Akademik Veri Yönetim Sistemi
32. Ulusal Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Kongresi, İstanbul, Türkiye, 10 - 13 Mayıs 2023, ss.420
COVID-19 infection has been associated with long-term cardiovascular complications such as hypertension, cardiac arrhythmia, cardiomyopathy, coagulopathy, and sudden cardiac death. There is also a risk of drug-induced hypertension when using methylphenidate and atomoxetine, which are widely prescribed for treating ADHD. Here, we present the case of an 11-year-old male patient who has been using atomoxetine for two years to treat ADHD and who developed systemic hypertension associated with COVID-19. We report an 11-year-old boy diagnosed with ADHD at eight years of age was under atomoxetine 40 mg/day treatment for the last two years. He and his parents were diagnosed with COVID-19 in October 2020. His parents reported that he continued to take his ADHD medication during the COVID-19 illness. He was admitted to the pediatrician for his headache complaint six months after he had COVID-19. His blood pressure was 150/100 mmHg. Upon detailed investigation, he was diagnosed with systemic hypertension, and no underlying cause of hypertension was found. It was concluded that his high blood pressure was a long-term complication of COVID-19. We reported the development of hypertension due to COVID in an 11-year-old male patient receiving atomoxetine 40 mg/day treatment. We think it is essential for child and adolescent psychiatrists to question whether patients have a COVID history before starting ADHD medication and add blood pressure measurement to their routine clinical practice